Earlier animal studies and case-control human studies based on healthcare database or histopathological data of donated human pancreata suggested that GLP-1-based therapies might increase the risks of pancreatitis and pancreatic cancer [7–9]. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.